Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | SCD | O00767 | 11/20 | 0.57 |
| ▸ | RBP4 | P02753 | 2/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259803 | 0.92 | EPHX2 (0.59) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL25414530 | 0.92 | EPHX2 (0.59) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL2946871 | 0.92 | EPHX2 (0.59) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL31381205 | 0.88 | SCD (0.61) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL20570261 | 0.87 | EPHX2 (0.52) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL2637115 | 0.86 | SCD (0.60) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL4170411 | 0.86 | RBP4 (0.65) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL9902820 | 0.85 | EPHX2 (0.50) | EPHX2SCDRBP4TTRKDM4E | |
| SCHEMBL1231588 | 0.84 | SCD (0.60) | EPHX2SCD | |
| SCHEMBL14412948 | 0.84 | EPHX2 (0.66) | EPHX2SCDRBP4TTRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119497709-A | Pyrimidine derivatives | ASKA 制药株式会社 | 2025-02-21 | — | — | CN | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20100152208-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2010-06-17 | — | — | US | disclosed |
| EP-2152719-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-02-17 | — | — | EP | disclosed |
| US-20100004287-A1 | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20090291955-A1 | Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
| WO-2008141455-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| EP-1951731-A1 | AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-08-06 | — | — | EP | disclosed |
| EP-1910352-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007056846-A1 | AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291955-A1 | Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, SREBF1 | EPHX2 1750/4885SCD 1/4885RBP4 601/4885 |
| US-20100152208-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, CPT1A | EPHX2 1208/4885SCD 1/4885RBP4 866/4885 |
| US-20100004287-A1 | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, CPT1A | EPHX2 1761/4885SCD 1/4885RBP4 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.